BTAI
BioXcel Therapeutics, Inc. Common Stock
stock NASDAQ

The truly high-risk case is BTAI. Their drug is already in use in hospitals, and approval for a home-use version is due on November 14th. This pipeline is estimated to generate between $400 million and $1.2 billion in revenue annually. However, the company's market capitalization is only $42 million, with $17 million in cash, $140 million in debt, and an annual loss of $51 million. It is insolvent and facing a cash flow crisis. The company has hired financial advisor MTS Health Partners to evaluate all strategic options, including pursuing a full acquisition, asset sale, or multinational joint development. The company also has five other pipelines/indications (including two successful Phase II clinical trials) halted due to financial difficulties. Even if approval is granted on November 14th, the drug won't even cover the cost of launching it to the market. It all depends on what price the pharmaceutical company offers to acquire it. A reasonable offer might be $1 billion, but given BTAI's financial difficulties, a mere $200 million for the drug rights is also possible (excluding company debt).

The truly high-risk case is BTAI. Their drug is already in use in hospitals, and approval for a home-use version is due on November 14th. This pipeline is estimated to generate between $400 million and $1.2 billion in revenue annually. However, the company's market capitalization is only $42 million, with $17 million in cash, $140 million in debt, and an annual loss of $51 million. It is insolvent and facing a cash flow crisis. The company has hired financial advisor MTS Health Partners to evaluate all strategic options, including pursuing a full acquisition, asset sale, or multinational joint development. The company also has five other pipelines/indications (including two successful Phase II clinical trials) halted due to financial difficulties. Even if approval is granted on November 14th, the drug won't even cover the cost of launching it to the market. It all depends on what price the pharmaceutical company offers to acquire it. A reasonable offer might be $1 billion, but given BTAI's financial difficulties, a mere $200 million for the drug rights is also possible (excluding company debt).